secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENXBIO Inc. (RGNX)
CIK:        0001590877
Form:       8-K
Filed at:   2021-11-02T23:59:59+00:00
Accession:  0001564590-21-053557
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

REGENXBIO Q3 net loss $58.4M; AbbVie collaboration for RGX-314 with $370M upfront
--------------------------------------------------------------------------------

- AbbVie collaboration: $370M upfront, up to $1.38B milestones, 50/50 U.S. profit share.
- Q3 revenue $30.8M (prior year $98.9M included $80M milestone); net loss $58.4M vs prior year net income $8.8M.
- Cash $533.5M; expects to fund operations into H2 2023, excluding AbbVie deal proceeds.
- RGX-314 Phase II: stable visual acuity and reduced anti-VEGF burden in wet AMD; 33% of DR patients improved ≥2 steps.
- IND for RGX-202 for Duchenne muscular dystrophy on track for end of 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590877/000156459021053557/0001564590-21-053557-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590877/000156459021053557/rgnx-8k_20211102.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-053557

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer